Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 12, 2012 - Issue 12
Submit an article Journal homepage
971
Views
43
CrossRef citations to date
0
Altmetric
Drug Profile

A review of paliperidone palmitate

Pierre Chue Department of Psychiatry, University of Alberta, Edmonton, AL, Canada. [email protected]; Department of Psychiatry, University of Alberta, Edmonton, AL, Canada. [email protected]
&
James Chue Clinical Trials and Research Program, Edmonton, AL, Canada; Clinical Trials and Research Program, Edmonton, AL, Canada
Pages 1383-1397 | Published online: 09 Jan 2014

References

  • Abott C, Keith S. Antipsychotic treatment and adherence in schizophrenia. In: Antipsychotic Long-acting Injections. Haddad P, Lambert T, Lauriello J (Eds). Oxford University Press, Oxford (2011).
  • Kane JM. Schizophrenia. N. Engl. J. Med. 334(1), 34–42 (1996).
  • Davis JM. Maintenance therapy and the natural course of schizophrenia. J. Clin. Psychiatry 46(11 Pt 2), 18–21 (1985).
  • McEvoy JP. Risks versus benefits of different types of long-acting injectable antipsychotics. J. Clin. Psychiatry 67(Suppl. 5), 15–18 (2006).
  • Llorca PM. Partial compliance in schizophrenia and the impact on patient outcomes. Psychiatry Res. 161(2), 235–247 (2008).
  • Schooler NR. Relapse and rehospitalization: comparing oral and depot antipsychotics. J. Clin. Psychiatry 64(Suppl. 16), 14–17 (2003).
  • Adams CE, Fenton MK, Quraishi S, David AS. Systematic meta-review of depot antipsychotic drugs for people with schizophrenia. Br. J. Psychiatry 179, 290–299 (2001).
  • Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia – a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 127(1–3), 83–92 (2011).
  • Davis JM, Matalon L, Watanabe MD, Blake L, Matalon L. Depot antipsychotic drugs. Place in therapy. Drugs 47(5), 741–773 (1994).
  • Chue P. Risperidone long-acting injection. Expert Rev. Neurother. 3(4), 435–446 (2003).
  • Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost–effectiveness. Expert Rev. Neurother. 9(1), 9–31 (2009).
  • Rainer MK. Risperidone long-acting injection: a review of its long term safety and efficacy. Neuropsychiatr. Dis. Treat. 4(5), 919–927 (2008).
  • Möller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. Drugs 67(11), 1541–1566 (2007).
  • Dursun S. An atypical long-acting injectable antipsychotic: implications for pharmacotherapy of schizophrenia. J. Psychopharmacol. (Oxford) 19(Suppl. 5), 3–4 (2005).
  • Love RC, Conley RJ. Long-acting risperidone injection. Am. J. Health. Syst. Pharm. 61(17), 1792–1800 (2004).
  • Faludi G. [The first long-acting atypical antipsychotic: new milestone in the treatment of schizophrenia]. Neuropsychopharmacol. Hung. 7(1), 22–27 (2005).
  • Harrison TS, Goa KL. Long-acting risperidone: a review of its use in schizophrenia. CNS Drugs 18(2), 113–132 (2004).
  • Ehret MJ, Fuller MA. Long-acting injectable risperidone. Ann. Pharmacother. 38(12), 2122–2127 (2004).
  • Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin. Ther. 26(12), 1994–2002 (2004).
  • Chue P. Risperidone long-acting injection. In: Antipsychotic Long-acting Injections. Haddad P, Lambert T, Lauriello J (Eds). Oxford University Press, Oxford (2011).
  • Lemon M. Risperidone long-acting injection: a brief overview. S. D. J. Med. 57(5), 171–172 (2004).
  • Naber D. Olanzapine pamoate for the treatment of schizophrenia. Expert Opin. Pharmacother. 12(4), 627–633 (2011).
  • Frampton JE. Olanzapine long-acting injection: a review of its use in the treatment of schizophrenia. Drugs 70(17), 2289–2313 (2010).
  • Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiatr. Dis. Treat. 6, 261–267 (2010).
  • Di Lorenzo R, Brogli A. Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiatr. Dis. Treat. 6, 573–581 (2010).
  • Owen RT. Olanzapine: a review of rapid and long-acting parenteral formulations. Drugs Today 46(3), 173–181 (2010).
  • Chue P, Chue J. Olanzapine pamoate. Exp. Opin. Pharmacother. 13(11), 1661–1670 (2012).
  • Owen RT. Paliperidone palmitate injection: Its efficacy, safety and tolerability in schizophrenia. Drugs Today 46(7), 463–471 (2010).
  • Citrome L. Paliperidone palmitate – review of the efficacy, safety and cost of a new second-generation depot antipsychotic medication. Int. J. Clin. Pract. 64(2), 216–239 (2010).
  • Bishara D. Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr. Dis. Treat. 6, 561–572 (2010).
  • Gilday E, Nasrallah HA. Clinical pharmacology of paliperidone palmitate a parenteral long-acting formulation for the treatment of schizophrenia. Rev. Recent Clin. Trials 7(1), 2–9 (2012).
  • Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs 24(3), 227–244 (2010).
  • Carter NJ. Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia. Drugs 72(8), 1137–1160 (2012).
  • Marino J, Caballero J. Paliperidone extended-release for the treatment of schizophrenia. Pharmacotherapy 28(10), 1283–1298 (2008).
  • Canuso CM, Battisti WP. Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania. Expert Opin. Pharmacother. 11(15), 2557–2567 (2010).
  • Dolder C, Nelson M, Deyo Z. Paliperidone for schizophrenia. Am. J. Health. Syst. Pharm. 65(5), 403–413 (2008).
  • Owen RT. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic. Drugs Today 43(4), 249–258 (2007).
  • Yang LP, Plosker GL. Paliperidone extended release. CNS Drugs 21(5), 417–425; discussion 426 (2007).
  • Dlugosz H, Nasrallah HA. Paliperidone: a new extended-release oral atypical antipsychotic. Expert Opin. Pharmacother. 8(14), 2307–2313 (2007).
  • Spina E, Cavallaro R. The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opin. Drug Saf. 6(6), 651–662 (2007).
  • Howland RH. Paliperidone extended-release tablets: a new atypical antipsychotic. J. Psychosoc. Nurs. Ment. Health Serv. 45(5), 15–18 (2007).
  • Chwieduk CM, Keating GM. Paliperidone extended release: a review of its use in the management of schizophrenia. Drugs 70(10), 1295–1317 (2010).
  • Nussbaum A, Stroup TS. Paliperidone for schizophrenia. Cochrane Database Syst. Rev. 16(2), CD006369 (2008).
  • Lautenschlager M, Heinz A. Paliperidone-ER: first atypical antipsychotic with oral extended release formulation. Expert Rev. Neurother. 8(2), 193–200 (2008).
  • Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiatr. Dis. Treat. 3(6), 869–897 (2007).
  • SakladSR. Texas Department of Health Services Formulary Monograph Paliperidone Palmitate Extended-Release Injectable Suspension (Invega® Sustenna™) 2010.
  • Chue P, MacKenzie E, Chue J, Baker G. A review of paliperidone extended release. Exp. Rev. Neurother. 12(12), XX–XX (2012).
  • de Leon J, Wynn G, Sandson NB. The pharmacokinetics of paliperidone versus risperidone. Psychosomatics 51(1), 80–88 (2010).
  • Vermeir M, Naessens I, Remmerie B et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab. Dispos. 36(4), 769–779 (2008).
  • All Wales Medicines Strategy Group Final Appraisal Recommendation – Advice no. 1611 Paliperidone palmitate (Xeplion®) November 2011.
  • Muller RH, Keck CM. Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles. J. Biotechnol. 113(1–3), 151–170 (2004).
  • Janssen-Ortho Inc. Invega Sustenna. Product Monograph (2010) (revised 21 July 2010).
  • Betz R, Gerber T, Hosten E et al. Paliperidone: 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9- hydroxy-2-methyl-1,6,7,8,9,9a-hexahydropyrido[1,2-a]pyrimidin-4-one. Acta Cryst. 67, 2945–2946 (2011).
  • Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab. Dispos. 21(6), 1134–1141 (1993).
  • Meuldermans W, Hendrickx J, Mannens G et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab. Dispos. 22(1), 129–138 (1994).
  • European Medicines Evaluation Agency. Invega European Public Assessment Report. EMEA, London, UK, Scientific discussion 1–58 (2007).
  • Ejsing TB, Pedersen AD, Linnet K. P-glycoprotein interaction with risperidone and 9-OH-risperidone studied in vitro, in knock-out mice and in drug–drug interaction experiments. Hum. Psychopharmacol. 20(7), 493–500 (2005).
  • Zhu HJ, Wang JS, Markowitz JS, Donovan JL, Gibson BB, DeVane CL. Risperidone and paliperidone inhibit p-glycoprotein activity in vitro. Neuropsychopharmacology 32(4), 757–764 (2007).
  • Samtani MN, Vermeulen A, Stuyckens K. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: a novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin. Pharmacokinet. 48(9), 585–600 (2009).
  • Cleton A, Rossenu S, Hough D et al. Assessment of the dose proportionality of paliperidone palmitate 25, 50, 100 and 150 mg eq., a new long-acting injectable antipsychotic following administration in the deltoid or gluteal muscles. Clin. Pharmacol. Ther. 83, S31 (2008).
  • Leysen JE, Janssen PM, Megens AA, Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55(Suppl.), 5–12 (1994).
  • Dremencov E, El Mansari M, Blier P. Distinct electrophysiological effects of paliperidone and risperidone on the firing activity of rat serotonin and norepinephrine neurons. Psychopharmacology (Berl.) 194(1), 63–72 (2007).
  • European Medicines Agency. Xeplion®. Summary of product characteristics.
  • Gopal S, Gassmann-Mayer C, Palumbo J, Samtani MN, Shiwach R, Alphs L. Practical guidance for dosing and switching paliperidone palmitate treatment in patients with schizophrenia. Curr. Med. Res. Opin. 26(2), 377–387 (2010).
  • Hough D, Lindenmayer JP, Gopal S et al. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 33(6), 1022–1031 (2009).
  • Perry R, Wolberg J, DiCrescento S. Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient tolerant of oral risperidone. Am. J. Health. Syst. Pharm. 69(1), 40–43 (2012).
  • Coppola D, Liu Y, Gopal S et al. A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia. BMC Psychiatry 12, 26 (2012).
  • Kramer M, Litman R, Hough D et al. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int. J. Neuropsychopharmacol. 13(5), 635–647 (2010).
  • Nasrallah HA, Gopal S, Gassmann-Mayer C et al. A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia. Neuropsychopharmacology 35(10), 2072–2082 (2010).
  • Gopal S, Hough DW, Xu H et al. Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study. Int. Clin. Psychopharmacol. 25(5), 247–256 (2010).
  • Pandina GJ, Lindenmayer JP, Lull J et al. A randomized, placebo-controlled study to assess the efficacy and safety of 3 doses of paliperidone palmitate in adults with acutely exacerbated schizophrenia. J. Clin. Psychopharmacol. 30(3), 235–244 (2010).
  • Bossie CA, Sliwa JK, Ma YW, Fu DJ, Alphs L. Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post hoc analyses of a randomized, double-blind clinical trial. BMC Psychiatry 11, 79 (2011).
  • Alphs L, Bossie CA, Sliwa JK, Ma YW, Turner N. Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial. Ann. Gen. Psychiatry 10(1), 12 (2011).
  • Sliwa JK, Bossie CA, Ma YW, Alphs L. Effects of acute paliperidone palmitate treatment in subjects with schizophrenia recently treated with oral risperidone. Schizophr. Res. 132(1), 28–34 (2011).
  • Hough D, Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M. Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 116(2–3), 107–117 (2010).
  • Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. A 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J. Psychopharmacol. (Oxford) 25(5), 685–697 (2011).
  • Kozma CM, Slaton T, Dirani R, Fastenau J, Gopal S, Hough D. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate: results from a clinical trial with a 52-week open-label extension (OLE). Curr. Med. Res. Opin. 27(8), 1603–1611 (2011).
  • Emsley R, Nuamah I, Hough D, Gopal S. Treatment response after relapse in a placebo-controlled maintenance trial in schizophrenia. Schizophr. Res. 138(1), 29–34 (2012).
  • Fleischhacker WW, Gopal S, Lane R et al. A randomized trial of paliperidone palmitate and risperidone long-acting injectable in schizophrenia. Int. J. Neuropsychopharmacol. 1–12 (2011).
  • Pandina G, Lane R, Gopal S et al. A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(1), 218–226 (2011).
  • Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 35(4), 1002–1008 (2011).
  • Gopal S, Pandina G, Lane R et al. A post hoc comparison of paliperidone palmitate to oral risperidone during initiation of long-acting risperidone injection in patients with acute schizophrenia. Innov. Clin. Neurosci. 8(8), 26–33 (2011).
  • Gopal S, Berwaerts J, Nuamah I et al. Number needed to treat and number needed to harm with paliperidone palmitate relative to long-acting haloperidol, bromperidol, and fluphenazine decanoate for treatment of patients with schizophrenia. Neuropsychiatr. Dis. Treat. 7, 93–101 (2011).
  • Furiak NM, Ascher-Svanum H, Klein RW et al. Cost–effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. Curr. Med. Res. Opin. 27(4), 713–730 (2011).
  • Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A. Cost–effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. J. Med. Econ. 15(5), 844–861 (2012).
  • All Wales Medicines Strategy Group Secreteriat Assessment Report- Advice no. 1611 Paliperidone palmitate (Xeplion®) October 2011.
  • North East Treatment Advisory Group (NETAG). Paliperidone depot injection (Xeplion®) for schizophrenia. 2011.
  • VA Pharmacy Benefits Management Service, Medical Advisory Panel, and VISN Pharmacist Executives. Olanzapine Pamoate (Zyprexa® Relprevv®) National Drug Monograph. December 2010.
  • Paliperidone Palmitate Extended-Release Injectable Suspension Invega® Sustenna™) Formulary Review Statewide Pharmacy and Therapeutics Committee Friday, 20 November 2009.
  • Edwards NC, Muser E, Doshi D, Fastenau J. The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving. J. Med. Econ. 15(4), 623–634 (2012).
  • Preston ST, Hegadoren K. Glass contamination in parenterally administered medication. J. Adv. Nurs. 48(3), 266–270 (2004).
  • Samtani MN, Gopal S, Gassmann-Mayer C, Alphs L, Palumbo JM. Dosing and switching strategies for paliperidone palmitate: based on population pharmacokinetic modelling and clinical trial data. CNS Drugs 25(10), 829–845 (2011).
  • Newton R, Hustig H, Lakshmana R et al. Practical guidelines on the use of paliperidone palmitate in schizophrenia. Curr. Med. Res. Opin. 28(4), 559–567 (2012).
  • Chue P, Emsley R. Long-acting formulations of atypical antipsychotics: time to reconsider when to introduce depot antipsychotics. CNS Drugs 21(6), 441–448 (2007).
  • Alphs L, Gopal S, Karcher K et al. Are the long-acting intramuscular formulations of risperidone or paliperidone palmitate associated with post-injection delirium/sedation syndrome? An assessment of safety databases. Curr. Drug Saf. 6(1), 43–45 (2011).
  • National Institute for Health and Clinical Excellence (2009) Schizophrenia: Core interventions in the treatment and management of schizophrenia in primary and secondary care (update), National Clinical Practice Guideline Number 82. National Collaborating Centre for Mental Health Commissioned by the National Institute for Health and Clinical Excellence.
  • Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs 26(5), 403–420 (2012).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.